Demystifying AI, ML and Natural Language Processing

RESEARCH INNOVATION





Sharang Phadke Product Manager



Peter Larson Software Engineer

≡ WSJ ▲ The AI Doctor Will See You Now

Artificial intelligence comes to the doctor's office, helping identify disease, monitor heart activity, stave off seizures



 \equiv

No longer science fiction, AI and robotics are transforming healthcare

NEW YORK POST

Google AI teaches itself to be smarter than doctors

By Mike Wehner, BGR November 30, 2016 | 1:57pm

Artificial Intelligence Continues to Change Health Care

Clinicians are getting smart new virtual partners to improve care.

By U.S. News Staff



Objectives

- Walk away with a better understanding of the terms:
 - o Artificial intelligence (AI)
 - Machine learning (ML)
 - Natural language processing (NLP)
- Feel more prepared to make informed decisions around the use cases of AI, ML, and NLP in your practice



Agenda

- Terms & Definitions
- Guiding Principles
- Machine Learning @ Flatiron
- Takeaways
- Q&A



Agenda

• Terms & Definitions


- Guiding Principles
- Machine Learning @ Flatiron
- Takeaways
- Q&A



Artificial Intelligence (AI)

Machine Learning (ML) Natural Language Processing (NLP)





Artificial Intelligence (AI):


the theory and development of computer systems **able to perform tasks that normally require human intelligence**, such as visual perception, speech recognition, decision-making, and translation between languages.











Machine Learning (ML):

the field of study that uses statistical techniques to give computers the **ability to learn without being explicitly programmed.**



Machine Learning: Recognizing Faces







Machine Learning: Recognizing Faces






Machine Learning: Recognizing Faces








Same or different person?





Sharang Phadke ~10 years ago






Natural Language Processing (NLP):

a collection of computational techniques that enable computers to analyze, understand, **derive meaning from and make use of human language.**



NLP: Identifying Sentence Structures

Visit note





Artificial Intelligence (AI)





Agenda

- Terms & Definitions
- Guiding Principles
- Machine Learning @ Flatiron
- Takeaways
- Q&A



Guiding Principles for Machine Learning at Flatiron Health



ML is math, not magic.

ML is built on a series of mathematical formulas, and understanding the errors these formulas make is important



ML is a tool, not a product.

ML will empower humans, not replace them.

It can enable new features, but ML is not a product we can use alone ML can make humans faster and more accurate, but it can't do everything.



ML is math, not magic





ML is math, not magic






ML is math, not magic






ML is a tool, not a product





ML will empower humans, not replace them





ML will empower humans, not replace them



ML is great at

- Sifting through lots and lots of examples
- Recognizing tiny patterns in data

$\bigcap_{n=1}^{\infty}\bigcap_{i=1}^{\infty}$ Humans are great at


- Synthesizing information
- Applying domain-specific knowledge
- Adapting to new information

Humans will always be necessary for

- Generating data for the model to learn from
- Evaluating the performance of ML models



Consider ML on a case by case basis




ML performs well today when ...

- The question is a simple problem statement
- The question involves pattern recognition
- There are a lot of examples available to learn from



Consider ML on a case by case basis



ML is a challenging fit when ...

- The problem requires synthesis and reasoning
- There is a large and complex knowledge base to learn
- There are many exceptions to the rule
- For those exceptions, there are few examples to learn from



Inform your decision making



\mathbf{X}

8

Understand the math:

What kinds of examples will be fed into the system to help it learn patterns? Identify the use case:

What question are we asking the ML model to answer for us?

How will ML be part of a larger product for my practice? Make ML work for you:

How will this use case of ML help with my day-to-day work?


How will the system deal with cases where the ML prediction is wrong?



Agenda

- Terms & Definitions
- Guiding Principles
- Machine Learning @ Flatiron
- Takeaways
- Q&A





Today, roughly 4% of all adult cancer patients enroll in clinical trials.





Data updated 08/13/2019

						Data updated	00/13/201
Q Filter by name	All trial statuses 👻	Select diseases *	All lines of therapy	•		Add cli	nical trial
iltered by: None.						Showing 14	of 14 rov
Trial name	Trial description		Status	÷	Disease	Line of therapy	
A7471042: Pfizer	Study Of Dacomitinib (PF	-00299804) In Advan	Pending		Breast Cancer Non-Small Cell Lun		I
BRE-1205	A Phase III Randomized	Double-blind, Placebo	Closed		Breast Cancer	None selected	I
BRE-2252	A Randomized Phase III	Trial of CDK Inhibitors	Pending		Non-Small Cell Lun	Adjuvant	1
BRE-2321	Anastrozole in Preventing	Breast Cancer in Po	Pending		Breast Cancer	Metastatic: 1st line	I
CRC-11182	A Phase II Study of the C	ombination of VEGF	Active_Recruiting		Colon Cancer	Metastatic: 1st line	1
CRC0101	Phase III, multicenter, op	en-label, three-arm, ra	Active, Recruiting		Colon Cancer Rectal Cancer	Metastatic: 3rd line and beyond	I
GU0002	A Phase 3 Randomized,	Double-blind, Multi-ce	Active, Recruiting		Bladder Cancer	Adjuvant	1
NCI-2014-00746	A Randomized Phase III	Trial of Endocrine The	Active, Recruiting		Breast Cancer	Metastatic: 2nd line	1
NCI-2014-02674	Randomized Phase II/III	Study of Nivolumab PI	Active, Recruiting		Non-Small Cell Lun	Induction Maintenance	I
NCI-2016-01595	A Randomized, Phase III	Trial to Evaluate the	Active, Recruiting		Breast Cancer	Adjuvant	I
NSCLC-1890	A Phase II Trial of Concu	rrent Chemoradiation	Active, Not Recruiting	9	Non-Small Cell Lun	Consolidation	1
PANC-0001	Randomized Study of TM	P1101 in Combination	Active, Recruiting		Pancreatic Cancer	Metastatic: 2nd line	I
REBECCA II: Danish Cancer Soci	Rehabilitation After Breas	t Cancer	Pending		Breast Cancer	Metastatic: 1st line	1
V3-MOMMO-01: Immunitor LLC	Open Label Immunothera	py Trial for Breast Ca	Pending		Breast Cancer	Metastatic: 1st line Metastatic: 2nd line	I

© 2013- Flatiron Health, Inc. All rights reserved. Privacy Policy | Acceptable Use Policy



Waiting for oncotrials.flatiron.com...

Screen patients using the visit list

= HONCOTRIALS Irials Patients Feasibility Reports

				Data updated	08/13/20
Q Filter by name	All trial statuses 👻 Select diseases 👻	All lines of therapy 👻		Add cli	nical trial
tered by: None.				Showing 14	of 14 rov
Trial name	Trial description	Status 🌩	Disease	Line of therapy	
A7471042: Pfizer	Study Of Dacomitinib (PF-00299804) In Advan	Pending	Breast Cancer Non-Small Cell Lun		I
BRE-1205	A Phase III Randomized Double-blind, Placebo	Closed	Breast Cancer	None selected	1
BRE-2252	A Randomized Phase III Trial of CDK Inhibitors	Pending	Non-Small Cell Lun	Adjuvant	:
BRE-2321	Anastrozole in Preventing Breast Cancer in Po	Pending	Breast Cancer	Metastatic: 1st line	I
CRC-11182	A Phase II Study of the Combination of VEGF	Active Recruiting	Colon Cancer	Metastatic: 1st line	:
CRC0101	Phase III, multicenter, open-label, three-arm, ra	Active, Recruiting	Colon Cancer Rectal Cancer	Metastatic: 3rd line and beyond	I
GU0002	A Phase 3 Randomized, Double-blind, Multi-ce	Active, Recruiting	Bladder Cancer	Adjuvant	:
NCI-2014-00746	A Randomized Phase III Trial of Endocrine The	Active, Recruiting	Breast Cancer	Metastatic: 2nd line	1
NCI-2014-02674	Randomized Phase II/III Study of Nivolumab Pl	Active, Recruiting	Non-Small Cell Lun	Induction Maintenance	1
NCI-2016-01595	A Randomized, Phase III Trial to Evaluate the	Active, Recruiting	Breast Cancer	Adjuvant	:
NSCLC-1890	A Phase II Trial of Concurrent Chemoradiation	Active, Not Recruiting	Non-Small Cell Lun	Consolidation	:
PANC-0001	Randomized Study of TMP1101 in Combination	Active, Recruiting	Pancreatic Cancer	Metastatic: 2nd line	1
REBECCA II: Danish Cancer Soci	Rehabilitation After Breast Cancer	Pending	Breast Cancer	Metastatic: 1st line	I
V3-MOMMO-01: Immunitor LLC	Open Label Immunotherapy Trial for Breast Ca	Pending	Breast Cancer	Metastatic: 1st line Metastatic: 2nd line	1

© 2013- Flatiron Health, Inc. All rights reserved. Privacy Policy | Acceptable Use Policy



Waiting for oncotrials.flatiron.com...

Screen patients using the visit list

	ials <u>Patients</u> F								Q Search 😆 Flatiron Demo 👻
GENERAL Notifications 1 Visit schedule	Suggested tria	als Show description	sicians • All locations • H	lide viewed appointments Print	0				
PATIENT RECRUITMENT New to practice Recent scans/pathology Suggested trials	Search by name or Filtered by: None.		All visit types 🔹 All trials 🕶	All statuses 👻					Showing 1-50 of 86 patients \ll $<$ $>$ \gg
ON-STUDY PATIENTS	Patient		Diagnosis	Visit Type		Physician	Location	Current status on tr	ial(s)
Active patients Follow-up patients Requires reconsent	Della Torp A035101	hy	Breast Cancer and 6 others	Treatment	8:00 am		Kelliview Cancer Specialists	NCI-2016-01595 V3-MOMMO-01: I A7471042: Pfizer 2 trials	Active Watching In Consenting Process Deemed Ineligible
	Vuon Kub A073496		Breast Cancer Fallopian Tube Cancer and 3 others	Treatment	8:15 am		Cancer Specialists of Lake	NCI-2016-01595 A7471042: Pfizer 2 trials	Candidate In Pre-screening Deemed Ineligible
	Mary Jane A017528	Ryan	Breast Cancer and 3 others	Office Visit	8:45 am	Ernser, Alessia	Cancer Center of Jaedenburgh	NCI-2016-01595 2 trials	 In Pre-screening Deemed Ineligible
	Greta L. S A088526	iteuber	Breast Cancer Mucosal Melanoma and 5 others	Treatment	9:00 am		Lake Danykaside Cancer Cli	NCI-2014-00746 2 trials	In Pre-screening Deemed Ineligible
	 Claudette A003684 	Homenick	Breast Cancer and 4 others	Treatment	9:15 am		Cancer Specialists of South	NCI-2014-00746 A7471042: Pfizer 2 trials	Active Candidate Deemed Ineligible
	Genelle L: A056174	arson	Breast Cancer	Office Visit	9:15 am	Klocko, Dagmar	South Aletha Cancer Clinic	NCI-2014-00746 BRE-2321 NCI-2016-01595	Watching In Pre-screening Deemed Ineligible
	Ollie X. St A023408	iedemann	Breast Cancer and 7 others	Office Visit	9:15 am	Barrows, Aurelia	Cancer Specialists of South	REBECCA II: Dan BRE-2321 NCI-2014-00746 NCI-2016-01595	Signed Main Study Consent In Pre-screening Screen Fail Deemed Ineligible
	Christina A050334	Weissnat	Breast Cancer and 3 others	Treatment	9:15 am		Kelliview Cancer Specialists	NCI-2016-01595 2 trials	 In Consenting Process Deemed Ineligible
	 Renae M. A010295 	Gottlieb	Breast Cancer and 3 others	Office Visit	9:30 am	Abbott, Nona	South Aletha Cancer Clinic	BRE-2321 NCI-2014-00746 NCI-2016-01595	 Discontinuation Discontinuation Watching
https://oncotrials.flatiron.com/onco	Curtis P. H	lerman	Colon Cancer	Office Visit	9:30 am	Dibbert, Lucy	South Aletha Cancer Clinic	CRC-11182 CRC0101	Watching Deemed Ineligible



A patient snapshot is shown in the sidebar

E MONCOTRIALS T	ials <u>Patients</u> Feasibility Reports	Della Torphy # A035101 DOB: 04/28/1982 (37 years old)	Set reminder Mark unviewed Close
GENERAL Notifications 1 Visit schedule	Suggested trials Show description	Intments Print OB/13/2019: A7471042: Pfizer: check scan results	Set on 08/05/2019 by Caroline Nightingate Edit Delete
PATIENT RECRUITMENT New to practice Recent scans/pathology	Search by name or MRN All Diagnoses All visit types All trials All statuses Filtered by: None. Wed., 08/14/2019	- Patient Note	Trials Search from all trials
Suggested trials	- Wed., 0019/2018	Add note	Active Trials
ON-STUDY PATIENTS Active patients Follow-up patients	Patient Diagnosis Visit Ty Della Torphy Breast Cancer Treatme A035101 and 6 others	Last edited by demo@lation.com on 10/10/2018	NCI-2016-01595 Show More ~ All sites: active, recruiting Active
Requires reconsent		Patient Clinical Info Open OncoEMR Documents	Trials to evaluate (3) Trials in screening (0) Archived Trials (2)
	Vuon Kub Breast Cancer Treatme A073496 Fallopian Tube Cancer and 3 others	nt Diagnosis	V3-MOMMO-01: Immunitor LLC pending Watching
	Mary Jane Ryan April 20 April 2	sit Encounter for Chemotherapy/Immunotherapy 10/10/2019 Other Disease Conditions	Breast Cancer Ø HER2 neg Ø
	Greta L. Steuber Breast Cancer Treatment Ad88526 Mucosal Melanoma and Schems	nt Osteoporosis 08/09/2019 Other Disease Conditions 08/09/2019 Other Anemia 08/09/2019	A7471042: Pfizer pending In Consenting Process
	Claudette Homenick Breast Cancer Treatmen A003684 and 4 others	nt Anemias Red Blood Cell Disorders Fever 08/03/2019 Other Disease Conditions	Breast Cancer HER2 neg REBECCA II: Danish Cancer S
	Genelle Larson Breast Cancer Office V A056174	Disease of blood and blood-forming organs, dhap doi:172015	pending
	Office V Office V	sit Offer Disease Condition 6/27/2019	Breast Cancer O HER2 pos O
	A023408 and 7 others	Come Dealess Conditions Encounter for Chemotherapy/Immunotherapy 04/27/2019 Other Disease Conditions	
	Christina Weissnat Breast Cancer Treatme A050334 and 3 others	nt Nausea with/without Vomiting 04/16/2019 Other Disease Conditions	
	Renae M. Gottlieb Breast Cancer Office V A010285 and 3 others	sit Breast Cancer 03/07/2019 Stage IIB (04/14/2019)	
	Curtis P. Herman Colon Cancer Office V A025105 and 4 others	sit Biomarkers 🜒	



A patient snapshot is shown in the sidebar

E foncotrials	rials <u>Patients</u> Feasibility Reports	Della Torphy # A035101 DDB: 04/28/1982 (37 years old) Set reminder Mark unviewed Close Close
GENERAL Notifications	Suggested trials Show description Wed., 08/14/2019 C > All physicians • All locations • Hide viewed appointments Print 0	Notifications:
PATIENT RECRUITMENT	Search by name or MRN All Diagnoses All visit types All trials All statuses	08/13/2019: A7471042: Pfizer: check scan results Set on 08/05/2019 by Caroline Nightingale Edit Delete
New to practice Recent scans/pathology	Filtered by: None.	Patient Note Trials Search from all trials
Suggested trials		Add note Active Trials
ON-STUDY PATIENTS Active patients	Patient Diagnosis Visit Type	Last edited by demolgifiatron.com on 101102018 All sites.addve, recruiting Show More ~
Follow-up patients Requires reconsent	Delia Torphy Breast Cancer Treatment A035101 and 6 others	Active Patient Clinical Info Open OncoEMR Documents Triats to evaluate (3) Triats in screening (0) Archived Triats (2)
Requires reconson	Vuon Kub Breast Cancer Treatment A073406 Fallopian Tube Cancer and 3 offens	V3-MOMMO-01: Immunitor LLC pending • Watching
	Mary Jane Ryan Breast Cancer Office Visit A017528 and 3 others	Encounter for Chemotherapy/Immunotherapy 10/10/2019 Breast Cancer Other Disease Conditions
	Greta L. Steuber Breast Cancer Treatment A088526 and 5 others	Osteoporosis 08/09/2019 A7471042: Pfizer Other Disease Conditions pending Other Anemia 08/09/2019 In Consenting Process
	Claudette Homenick Breast Cancer Treatment AD03684 and 4 others	Anemias Red Blood Cell Disorders Breast Cancer Fever 08/03/2019 Other Disease Conditions BEBECCA II: Danish Cancer S
	Genetile Larson A056174 Genetile Larson Office Visit	Disease of blood and blood-forming organs, unsp 06/27/2019 Beelen hemstelanie condition
	Ollie X. Stiedemann Breast Cancer Office Visit A023408 and 7 others	Odings Internationage Conductors Breast Cancer Edema 06/27/2019 Other Disease Conditions Image: Conditions Encounter for Chamotherapy/Immunotherapy 04/27/2019 Other Disease Conditions Image: Conditions
	Christina Weissnat Breast Cancer Treatment A050334 and 3 others	Nausea with/without Vomiting 04/16/2019 Other Disease Conditions
	Renae M. Gottlieb Breast Cancer Office Visit A010295 and 3 others	Breast Cancer 03/07/2019 Stage IB (04/14/2019)
	Curtis P. Herman Colon Cancer Office Visit and 4 others	Biomarkers 🕐



Metastatic status is usually only in visit notes

OCSA Oncology and Hematology 1522 Hillview Drive Suite 420, Los Allos, CA 94024-5300 Phone: 650-559-6040 Fax: 650-559-1772

Patient Name: Young, Elizabeth Theresa

Patient Number: 12498

Date: 8/23/2019 Date Of Birth: 1/12/1957

FOLLOW UP VISIT Oncology

Chief Complaint

Exactle is a lowely (2) year of female with a history of breast cancer that was treated in 2013. Site had done well following adjuvant hereany dne was only able to complete by years of armsets escordary to talgues and body aches. She has a 3 mech thadory of lower to pain. She had been hiking the inca trial and initially altibuted the pain to exercise. A Xing followed by scan indicates disease at 1.4 S and 6. She underwent to which is positive for metistatic previous cancer comploadly consistent with the primary breast disease.

History of Present Illness

Stage II breast cancer in 2013 s/p lumpectomy with chemo ra the lumbar spine, No other complaints back pain at 1-3 control

positive for metastatic breast cancer morphology

Past Medical History
Allergies
TETRACYCLINES

Medications

Inside Drug Script Date Qty Rfls Instructions CLONIDINE HCL 0 2MG TABLET 8/22/2004 30 1 1 p.o. g. day while awake pm Lasix 20 mg tablet 5/30/2015 30 0 1 p o g dav LOTENSIN 10MG TABLET 8/22/2004 30 1 1 p.o. g. day while awake pm TETRACYCLINE 500MG CAPSULE 8/22/2004 30 0 1 p.o. g. day while awake pm ZANTAC 150MG GELDOSE CAP 8/22/2004 30 1 1 p.o. q. day while awake pm

Review Of Systems

Pain Description: A slow or weak pain, not very sudden or strong Patient stated pain level: : No pain. A 10 point review of systems is otherwise negative except as mentioned fatigue. No fever. No rigors. No weight loss. No night sweats. No generalized weakness. Appetite good. No sleep distutance.

HEENT: Patient reports No blurred vision. No double vision. No hearing loss. No mouth sores.

Respiratory: Patient reports No difficulty breathing reported. No wheezing. No cough. No hemophysis. Gastrointestinal: Patient reports No nausea. No vomiting. No dysphagia. No heartburn. No abdominal pain. No diarrhea. No constipation

No melena. No hematochezia. Genitourinary: Patient reports No hematuria. No dysuria. No urgency, No incontinence, back pain. No limited range of motion, bone

Page 1 of 3

paint. Integumentary: Patient reports No rash. No pruritis. Neurological: Patient reports No headsche. No toata weakness. No paralysis. No paresthesias. No speech impairment. Hematologica: Patient reports No acressive or spontaneous teleding or bruising. Mental Health: Patient Reports No anxiety: no depression; no insomnia; no painc disorder. Towa. Biblinh Towa DB (1210)?(1310).

Patient is excluded from depression screening for the following reason: Patient Refused

Vitals Signs Vitals on 1/1/2007 1:07:51 PM: Height=67in, Weight=112lb, Temp=97f, Pulse=57, Resp=18, SystolicBP=122, DiastolicBP=79

Physical Examination

General: Skin: No actorymosis. No petechiae. No Jaundice. No Rash. Skin: No achormal skin lesions noted. Head: Not accessed. Pupta are count. COM. PERRIA. Ears. Nose, Throat, and Mouth: Normal crait muctosa and oropharyox. Neek: Neck is suited. No correct masses consent. Tachea is midline. No thyromecalw



🗮 🔰 ONCOTRIALS' Tria	ls <u>Patients</u>	Verna Frank #A12345	DOB: 06/23/1947 (72 years o	ld)	Set reminder	Deem ineligible	Close
GENERAL Notifications Visit Schedule	Active Patien	Notification: 07/01/18: Document requires signal	ure. Download document, version	n 2.000.		Edit	Delete
PATIENT RECRUITMENT	Search by name o	Add patient note		Trials 0		Search fron	n all trials
New patients Recent scans / pathology		Patient Clinical Info	Open in OncoEMR	Active trials			
Suggested trials	Patient	Diagnoses		NSCLC - PDL1- 32342 All sites: active, recruiting		Show	more 🗸
ON STUDY PATIENTS	Clara Gomez 81942	Essential (primary) hypertension	01/21/14	Active by janedoe@flatiron.co			
Active patients Follow-up patients	Verna Frank 88886	Non-small cell lung cancer Stage IIa (10/05/16)	11/04/11		als in screening (3)) Archived tr	ials (15)
Requires reconsent	00000	Polycythemia vera	09/23/13	NSCLC-1234 Active, recruiting Watching by janedoe@flatiron	n.com. "Waiting on s	scan"	
	Cecelia Gibbs	Disease status 0			Likely		
	Elnora Lee 94375	NSCLC model Metastatic disease	Likely last updated: 09/21/2017	PD-L1 positive)		
	Tula Simpson	Patient's disease is confirmed to be confirmed to be	e: metastatic non-metastatic	Active, recruiting Watching by janedoe@flatiron 		scan"	
	34232	Biomarkers 1		Lung cancer Metastatic	Likely		
		ROS1	02/15/2017: Positive	LUN - 34235			
	Maria Sanche 11244	PD-L1	01/27/2017: Positive	Active, recruiting Not statused			
	Tony Amier	EGFR	02/15/2017: Negative	Lung cancer 🔮 Metastatic 🤗			
	32223	ALK	02/15/2017: Negative	NTRK fusion @ BRAF positive @			
	Rei Arthur 49923	Drug order history		On Nivolumab			
		Ado-trastuumab emtansine	First Order: 02/01/2017				



Why did we choose to use ML for this application?

Recognizing documented evidence of metastatic status in a patient's chart

OCSA Oncology and Hematology 1522 Hillview Drive Suite 420. Los Altos. CA 94024-5300 Phone: 650-559-6040 Fax: 650-559-1772 Patient Name: Young, Elizabeth Theresa Date: 8/23/2019 Patient Number: 12498 Date Of Birth: 1/12/195 FOLLOW UP VISIT

Oncology

Chief Complaint

Eitzabeth is a lowely 62 year old female with a history of breast cancer that was treated in 2013. She had done well following activuant therapy she was only able to complete 3 years of arimdex secondary to fatigues and body aches. She has a 3 month history of lower back pain. She had been hiking the Inca Irail and initially attributed the pain to exercise. A Xray followed by scan indicates disease at 1.4.5 and 6. She underwent a bx which is positive for metastalic breast cancer morphology consistent with the primary breast disease.

History of Present Illness

Stage II breast cancer in 2013 s/p lumpectomy with chemo radiation followed by three years of Arimidex. Recent evidence of disease in the lumbar spine. No other complaints back pain at 1-3 controlled with OTC motrin.

Past Medical History

Allergies

Medication

Inside	Drug	Script Date	Qty	Rfls	Instructions
	CLONIDINE HCL 0.2MG TABLET	8/22/2004	30	1	1 p.o. q. day while awake pm
Y	Lasix 20 mg tablet	5/30/2015	30	0	1 p.o. q. day
	LOTENSIN 10MG TABLET	8/22/2004	30	1	1 p.o. q. day while awake pm
	TETRACYCLINE 500MG CAPSULE	8/22/2004	30	0	1 p.o. q. day while awake pm
	ZANTAC 150MG GELDOSE CAP	8/22/2004	30	1	1 p.o. q. day while awake pm

Review Of Systems

Pain Description: A slow or weak pain, not very sudden or strong Patient stated pain level: : No pain. A 10 point review of systems is ise negative except as mentioned. fatigue. No fever. No rigors. No weight loss. No night sweats. No generalized weakness. Appetite good. No sleep disturbance

HEENT: Patient reports No blurred vision. No double vision. No hearing loss. No mouth sores Respiratory: Patient reports No difficulty breathing reported. No wheezing, No cough, No hemophysis

Gastrointestinal: Patient reports No nausea. No vomiting. No dysphagia. No hearthum. No abdominal pain. No diarthea. No constituation No melena. No hematochezia

Genitourinary: Patient reports No hematuria. No dysuria. No urgency. No incontinence. back pain. No limited range of motion. bone

ML performs well today when ...

- The question is a simple prob statement
- The question involves pattern recognition
- There are a lot of examples available to learn from



Magic? Math!





How is the model trained?

Step 1: Extract snippets of text from patient documents

Patient Docs

Text Snippets

Patient is early stage

Bone mets present


Recurrence

Patient is a sports fan

Local disease


Step 2: Record how frequently each snippet is in metastatic patients' document vs. non-metastatic patients.

Text Snippets





How does the model make inferences?





How do we measure success?



when an inference is surfaced



How does the model handle instances when it's not correct?

Is clear when it doesn't know - surfaces the inference as "Unknown"

Leaves room for human input

Disease status 🕕	
NSCLC model Metastatic disease	Unknown last updated: 09/21/2017
Patient's disease is confirmed to be: me	etastatic non-metastatic





Inform your decision making





8

Understand the math:

The OncoTrials feature uses examples of patients we know are metastatic or not

Identify the use case:

Determines "Is there documented evidence that the patient is metastatic?"

Enhances the overall patient matching workflow in OncoTrials

Make ML work for you:

Narrows down the list of patients to review for trials

The model has an "Unknown" category when uncertain, and allows room for human input



Agenda

- Terms & Definitions
- Guiding Principles
- Machine Learning @ Flatiron
- Takeaways
- Q&A



Takeaways

Artificial Intelligence (AI)

Machine Learning (ML) Natural Language Processing (NLP)

Ask the key questions



Understand the math



Identify the use case

8

Make ML work for you







We want to hear from you!



Questions, comments, product feedback? Come visit us at the **<u>New Features</u>** booth



